Baillie Gifford & Co. Purchases 1,626,657 Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Baillie Gifford & Co. lifted its position in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 10.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,775,860 shares of the biotechnology company's stock after acquiring an additional 1,626,657 shares during the period. Baillie Gifford & Co. owned approximately 6.56% of Adaptimmune Therapeutics worth $15,944,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently modified their holdings of ADAP. Boulder Hill Capital Management LP bought a new position in Adaptimmune Therapeutics during the 1st quarter worth approximately $143,000. Renaissance Technologies LLC increased its holdings in Adaptimmune Therapeutics by 28.3% in the second quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company's stock worth $1,742,000 after purchasing an additional 394,566 shares in the last quarter. Long Focus Capital Management LLC lifted its stake in Adaptimmune Therapeutics by 15.6% in the second quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company's stock valued at $12,037,000 after buying an additional 1,662,184 shares during the period. Vontobel Holding Ltd. grew its holdings in Adaptimmune Therapeutics by 230.8% in the third quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 30,000 shares during the period. Finally, Fullcircle Wealth LLC bought a new stake in Adaptimmune Therapeutics in the third quarter valued at $33,000. Institutional investors and hedge funds own 31.37% of the company's stock.

Adaptimmune Therapeutics Stock Down 2.9 %

NASDAQ ADAP traded down $0.02 during trading hours on Wednesday, reaching $0.77. 1,542,929 shares of the company were exchanged, compared to its average volume of 1,631,056. Adaptimmune Therapeutics plc has a 1 year low of $0.42 and a 1 year high of $2.05. The business's 50 day simple moving average is $0.91 and its 200-day simple moving average is $1.04. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.09 and a current ratio of 3.09.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The biotechnology company reported $0.27 earnings per share for the quarter. The business had revenue of $128.23 million during the quarter, compared to analyst estimates of $58.00 million. Adaptimmune Therapeutics had a negative return on equity of 116.80% and a negative net margin of 51.25%. On average, equities research analysts predict that Adaptimmune Therapeutics plc will post -0.23 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ADAP. StockNews.com raised shares of Adaptimmune Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 13th. HC Wainwright reiterated a "buy" rating and issued a $4.00 target price on shares of Adaptimmune Therapeutics in a report on Tuesday, August 13th.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.